Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS clinical trial group study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1444-1449

  Dezube, Bruce J ^a   Von Roenn, Jamie H ^a   Holden Wiltse, Jeanne ^a   Cheung, Tony W ^a   Remick, Scot C ^a   Cooley, Timothy P ^a   Moore, Jeff ^a   Sommadossi, Jean Pierre ^a   Shriver, Sharon L ^a   Suckow, Carol W ^a   Gill, Parkash S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANGIOGENESIS; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR VASCULARIZATION; URTICARIA;

EID: 0031897809     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1444     Document Type: Article

References (20)

1. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
2. Pluda JM: Tumor-associated angiogenesis: Mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 24:203-218, 1997
3. Biggar RJ, Rabkin CS: The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am 10:997-1010, 1996
4. Li JJ, Huang YQ, Moscatelli D, et al: Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome-associated Kaposi sarcoma tissue and derived cells. Cancer 72:2253-2259, 1993
5. Masood R, Cai J, Zheng T, et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94:979-984, 1997
6. Salahuddin SZ, Nakamura S, Biberfeld P, et al: Angiogenic properties of Kaposi's sarcoma-derived cells after long-term culture in vitro. Science 242:430-433, 1988
7. Kusaka M, Sudo K, Fujita T, et al: Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070-1076, 1991
8. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555-557, 1990
9. Figg WD, Yeh HJ, Thibault A, et al: Assay of the antiangiogenic compound, TNP-470, and one of its metabolites, AGM 1883, by reverse-phase, high performance liquid chromatography in plasma. J Chromatogr 652:187-194, 1994
10. Moore JD, Sommadossi J-P, ACTG 215 Study Team: Determination of o-(chloroacetylcarbamoyl)fumagillol (TNP-470; AGM-1470) and two metabolites in plasma by high-performance liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spect 30:1707-1715, 1995
11. Gomeni R, Gomeni C: Interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 11:345-361, 1978
12. Levy T, Kudelka A, Verschraegen CF, et al: A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Proc Am Soc Clin Oncol 37:166, 1996 (abstr)
13. Ingber DE. Discovery of TNP-470 and other angiogenesis inhibitors, in Teicher BA (ed): Cancer Therapeutics: Experimental and Clinical Agents. Totowa, NJ, Humana, 1997, pp 283-298
14. Cretton-Scott E, Placidi L, McClure H, et al: Pharmacokinetics and metabolism of 0-(chloroacetyl-carbamoyl)fumagillol (TNP-470, AGM-1470) in rhesus monkeys. Cancer Chemother Pharmacol 38:117-122, 1996
15. Placidi L, Cretton-Scott E, de Sousa G, et al: Disposition and metabolism of the angiogenic moderator 0-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. Cancer Res 55:3036-3042, 1995
16. Ezekowitz A, Mulliken J, Folkman J: Interferon alpha therapy of haemangiomas in newborns and infants. Br J Haematol 79:67-68, 1991
17. White CW, Sondheimer HM, Crouch EC, et al: Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a. N Engl J Med 320:1197-1200, 1989
18. Estey E, Hoth D, Simon R, et al: Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep 70:1105-1115, 1986
19. Teicher BA, Holden SA, Ara G, et al: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57:920-925, 1994
20. Teicher BA, Dupuis NP, Robinson MF, et al: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7:237-243, 1995